Interestingly, endogenous decoy receptor 3, a soluble receptor against FasL, has been correlated to FasL loss of sensitivity of pancreatic adenocarcinoma by antagonistically blocking the growth inhibition signals [26,34]. Here, TNFRSF6B is linked to pancreatic adenocarcinoma.